BACKGROUND: Coronavirus disease 2019 (COVID-19) has spread almost all regions of the world and caused great loss to the whole body of mankind . Thus, numerous clinical trials were conducted to find specific medicine for COVID-19 recently . However, it remains unanswered whether they are beneficial .
OBJECTIVE: This study aimed to evaluate the efficiency and safety of the COVID-19 medicine .
METHODS: Studies were determined through searching PubMed, Embase, Cochrane Library, and Medline . The studies of COVID-19 medicine were involved with eligible end points containing mortality, discharge rate, rate of clinical improvement, and rate of serious adverse events .
RESULTS: A total of 33 studies involving 37,879 patients were included in our study, whose intervening measures contained three major types of COVID-19 medicine, ACEI/ARB, antiviral medicine, and chloroquine/hydroxychloroquine . Compared to control group, COVID-19 drugs have no distinct effect on mortality (RR , 0.93; 95% CI , 0.79-1.11, Pâ=â.43) and discharge rate (RR , 1.06; 95% CI , 0.98-1.14, Pâ=â.13). However, antiviral medicine presents the obvious advantage in clinical improvement (RR , 1.11; 95% CI , 1.01-1.23, Pâ <â.05). In addition, the serious adverse events rate (RR , 0.75; 95% CI , 0.63-0.88, Pâ <â.05) of COVID-19 medicine is lower than control group .
CONCLUSION: The results indicated antiviral medicine was potential specific medicine for COVID-19 treatment by improving clinical symptoms, but it failed to increase the discharge rate and reduce mortality . Chloroquine/hydroxychloroquine and ACEI/ARB had no significant effect on treatment of COVID-19, thus they were not recommended for routine medication . Moreover, more trials are needed to find effective drugs to lower the mortality of COVID-19 patients.